These observations are consistent with our results; COMP is overexpressed in BC patients and associated with ER and PR (19); GSEA indicated that COMP overexpression had significantly enriched the estrogen response and EMT pathways in both TC and BC and may promote TC and BC progression, thereby, increasing the risk of these double primary malignancies. Here, COMP is linked to breast cancer.